Solos Endoscopy, Inc. Reports a 30% Increase in Sales for June 2010 as Compared to June 2009

Tuesday, July 13, 2010 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, July 13 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to report the Company has

generated $47,247 in sales for the month of June 2010 versus $36,173 for the same month in 2009, which is a 30% increase. Solos Endoscopy generates its revenues
through the sale of its extensive line of medical instruments, which include imaging systems, hand held surgical instruments and endoscopic equipment.

The results are better than expected as Solos expects this positive trend to continue throughout the remainder of 2010 with new product development and market expansion. As part of the product development plan, Solos announced during the first six months of 2010 that the Company is developing a new polymer dilator and a relay lense adapter system for the MammoView® Breast Endoscopy System. In addition, Solos successfully completed Phase One (of Four) requirements for the ISO 13485 quality management system (QMS) initiative, which is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union and Canada.

The Company's unaudited 2nd quarter financial statements will soon be available to view on the Pink Sheets at www.pinksheets.com.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE Solos Endoscopy, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook